Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ImmunityBio, Inc. < Previous 1 2 Next > ImmunityBio to Participate in the Jefferies London Healthcare Conference October 27, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting June 06, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ May 23, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting April 28, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer April 25, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ April 01, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility February 15, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer February 14, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy January 31, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival January 18, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness January 12, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Awarded Seminal Patent on Natural Killer Cells January 04, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing December 20, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines November 18, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio to Present at the Jefferies London Healthcare Conference November 04, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease October 19, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date October 13, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy October 04, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial September 13, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives September 07, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting September 01, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion August 16, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent July 27, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19 July 14, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients June 28, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer June 15, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients June 10, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa May 25, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference May 24, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021 May 20, 2021 From ImmunityBio, Inc. Via Business Wire Tickers IBRX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.